OPay Ltd. (OPAY), the Nigerian FinTech app, has postponed its IPO indefinitely after the stock did not start trading today, as expected, according to Street sources familiar with the situation, IPOScoop has learned. Clients of a major firm have been notified that it was withdrawing from the IPO. It’s highly unusual for an IPO to […]
October 30, 2026 Read MoreAspen Neuroscience (ASPE), a biotech developing a stem cell therapy to treat patients with Parkinson’s Disease, priced its IPO at $15.00 – the low end of its range – and sold 9.375 million shares – the number in the prospectus – to raise $140.63 million on Thursday night, Oct. 29, 2026. The San Diego-based biotech’s […]
Read MoreSoftBank-backed OPay Ltd (OPAY), the parent of Nigeria’s No. 1 digital banking platform, priced its IPO at $19.00 – the low end of its range – and sold 16 million American Depositary Shares (ADS) to raise $304 million on Thursday night, Oct. 29, 2026. Each ADS represents 10 ordinary shares. Fast forward to Friday afternoon: […]
October 29, 2026 Read MoreBambusa Therapeutics (BBTX) upsized its IPO at pricing to 10.55 million shares – up from 9.38 million shares – and priced the IPO at $16.00 – the mid-point of its range – to raise $168.8 million on Thursday night, Oct. 29, 2026. The Boston biotech’s stock slid in its NASDAQ debut – opening at $14.88 […]
Read MoreBHAV Acquisition Corp. II (BHAIU) raised $100 million tonight – becoming the second SPAC IPO in the $100 million club to get priced this week. Piscataway, N.J.-based BHAV Acquisition II priced 10 million units at $10.00 each to raise $100 million on Wednesday night, Oct. 28, 2026, according to its SEC filing and the company’s […]
October 28, 2026 Read MoreAnthropic (ANT Proposed) pulled back the curtain on its IPO by filing its long-awaited S-1 this morning – Monday, Oct. 26, 2026. The San Francisco-based AI company, known for Claude, did not disclose the terms for its IPO in its S-1 filing. The IPO pros expect that Anthropic’s IPO could raise about $75 billion – […]
October 26, 2026 Read MoreAspen Neuroscience, Inc. (ASPE Proposed), a Phase 1/2a biotech targeting Parkinson’s Disease, unveiled the terms for its $150 million IPO early today – Monday, Oct. 26, 2026. The San Diego-based biotech is offering 9.38 million shares at a price range of $15.00 to $17.00 to raise $150 million, if priced at the $16.00 mid-point of […]
Read MoreBambusa Therapeutics (BBTX Proposed), a clinical biotech developing drugs to treat atopic dermatitis (“AD”) and COPD, set the terms and launched its $150 million IPO early today – Monday, Oct. 26, 2026 – with plans to price the deal this week. Bambusa Therapeutics, Inc. is offering 9.38 million shares at a price range of $15.00 […]
Read MoreOPay Ltd. (OPAY Proposed), the parent of Nigeria’s No. 1 digital banking platform, disclosed the terms for its $320 million IPO after the closing bell on Friday, Oct. 23, 2026. SoftBank-backed OPay Ltd. is offering 16 million American Depositary Shares (ADS) at a price range of $19.00 to $21.00 to raise $320 million, if priced […]
October 23, 2026 Read MoreLycia Therapeutics (LYCA) upsized its IPO at pricing to 17.64 million shares – up from 14.7 million shares in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $317.52 million on Thursday night, Oct. 22, 2026. Lycia’s stock jumped in its NASDAQ debut – opening at […]
October 22, 2026 Read More